D3 Bio, a Shangai, China-based global biotechnology company focused on developing and commercializing precision medicines to improve or replace existing standard-of-care treatments that do not fully meet patient needs, launched today with US$200m in Series A financing.
Backers included Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s Corporate Venture Fund, among others.
The company intends to use the funds for the development of its portfolio in oncology and immunology.
Led by George Chen, MD, co-founder, Chairman and CEO, D3 Bio is a globally-focused biotechnology company developing and commercializing precision medicines to improve or replace existing oncology and immunology standard-of-care treatments that fail to or don’t fully meet significant patient needs. The company collaborates with world-class partners across many geographic areas, integrating deep clinical and market insights about the healthcare treatment landscape with science and technological development through a progressive, iterative cycle of Development to Discovery and back to Development.
Dr. Chen is an oncologist by training, with a successful track record in the multinational pharmaceutical industry. After receiving his medical degree from the Shanghai Medical College of Fudan University and his MBA from the Wharton School of Business at the University of Pennsylvania, he held senior research, management, business development, medical affairs and drug development positions at leading institutions and multi-national companies, including the National Institutes of Health, Eli Lilly, GlaxoSmithKline, Johnson & Johnson and AstraZeneca. Dr. Chen’s experience includes regulatory registrations and market introductions of blockbuster drugs in both the US and Chinese markets, including more than 70 Investigational New Drug (IND) and more than 30 New Drug Application (NDA) approvals.